Clinical trials
Observational Lung Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Terminated | 6 |
| Unknown status | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital, Brest | 3 |
| AstraZeneca | 2 |
| Aeris Therapeutics | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil | 1 |
| Blueprint Medicines Corporation | 1 |
| Centre Hospitalier Régional d'Orléans | 1 |
| Centre Hospitalier Universitaire Dijon | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| Centre Hospitalier de Saint-Denis | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases | 25 |
| Pulmonary Disease, Chronic Obstructive | 5 |
| Dyspnea | 3 |
| Respiratory Tract Diseases | 3 |
| Asthma | 2 |
| Carcinoma, Bronchogenic | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Heart Diseases | 2 |
| Heart Failure | 2 |
| Lung Diseases, Obstructive | 2 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.